RISS 학술연구정보서비스

검색
다국어 입력

http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.

변환된 중국어를 복사하여 사용하시면 됩니다.

예시)
  • 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
  • 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
닫기
    인기검색어 순위 펼치기

    RISS 인기검색어

      Topical brimonidine as an effective adjuvant to local anesthetics for post-treatment erythema and pain reduction = Topical brimonidine as an effective adjuvant to local anesthetics for post-treatment erythema and pain reduction

      한글로보기

      https://www.riss.kr/link?id=A104221686

      • 0

        상세조회
      • 0

        다운로드
      서지정보 열기
      • 내보내기
      • 내책장담기
      • 공유하기
      • 오류접수

      부가정보

      다국어 초록 (Multilingual Abstract)

      Background: There are few pharmacologic options to reduce laser-associated post treatment erythema and to extend anesthesia duration. Development of a novel adjuvant agent to topical lidocaine cream is required.
      Objectives: This study aimed to evaluate the efficacy and safety of a combination of topical brimonidine and EMLA<sup>®</sup> as an aid for post treatment erythema and pain.
      Methods: A total of 15 Korean subjects were randomized to receive a split-face, subject-blind application of a mixture of brimonidine and EMLA<sup>®</sup> on one side and only EMLA<sup>®</sup> on the other side of the face for anesthesia. After performing 1,550 nm erbium-glass fractionated laser, post-treatment erythema and pain were assessed at four time points: immediately after resurfacing, 30 minutes after, 60 minutes after, and 1 day after.
      Results: A combination of brimonidine and EMLA<sup>®</sup> significantly lowered post treatment erythema until 60 minutes after the laser procedure. Furthermore, 30 and 60 minutes after the procedure, patients reported significantly lower post-procedural pain on the side where the mixture of brimonidine and EMLA<sup>®</sup> was applied.
      Conclusion: Topical brimonidine can be used as an effective adjuvant agent to lidocaine-based topical anesthetics.
      번역하기

      Background: There are few pharmacologic options to reduce laser-associated post treatment erythema and to extend anesthesia duration. Development of a novel adjuvant agent to topical lidocaine cream is required. Objectives: This study aimed to evalua...

      Background: There are few pharmacologic options to reduce laser-associated post treatment erythema and to extend anesthesia duration. Development of a novel adjuvant agent to topical lidocaine cream is required.
      Objectives: This study aimed to evaluate the efficacy and safety of a combination of topical brimonidine and EMLA<sup>®</sup> as an aid for post treatment erythema and pain.
      Methods: A total of 15 Korean subjects were randomized to receive a split-face, subject-blind application of a mixture of brimonidine and EMLA<sup>®</sup> on one side and only EMLA<sup>®</sup> on the other side of the face for anesthesia. After performing 1,550 nm erbium-glass fractionated laser, post-treatment erythema and pain were assessed at four time points: immediately after resurfacing, 30 minutes after, 60 minutes after, and 1 day after.
      Results: A combination of brimonidine and EMLA<sup>®</sup> significantly lowered post treatment erythema until 60 minutes after the laser procedure. Furthermore, 30 and 60 minutes after the procedure, patients reported significantly lower post-procedural pain on the side where the mixture of brimonidine and EMLA<sup>®</sup> was applied.
      Conclusion: Topical brimonidine can be used as an effective adjuvant agent to lidocaine-based topical anesthetics.

      더보기

      동일학술지(권/호) 다른 논문

      동일학술지 더보기

      더보기

      분석정보

      View

      상세정보조회

      0

      Usage

      원문다운로드

      0

      대출신청

      0

      복사신청

      0

      EDDS신청

      0

      동일 주제 내 활용도 TOP

      더보기

      주제

      연도별 연구동향

      연도별 활용동향

      연관논문

      연구자 네트워크맵

      공동연구자 (7)

      유사연구자 (20) 활용도상위20명

      이 자료와 함께 이용한 RISS 자료

      나만을 위한 추천자료

      해외이동버튼